Literature DB >> 25532386

[Clinical characteristics research of shenmai injection treating tumor based on hospital information system in real world].

Yuan-Chun Hu, Yan-Ming Xie, Wei Yang, Yong-Yan Wang, Lian-Xin Wang, Hao Tang, Yan Zhuang.   

Abstract

The study was to research the clinical characteristics of Shenmai injection treating tumor based on hospital information system, including the characteristics of the age, the sex, the dosage, the course of the treatment and the combination drugs. The data of tumor patients injected with Shenmai injection was analyzed. The information was collected from the hospital information system (HIS) in twenty hospitals of grade III-A. The method of frequencies and association rules was used in this reaearch. The patients over 45 years old were up to 3 338, about 79.36% of the whole. The ratio of male and female was 1.73: 1. The hospitalization day between 15 and 28 was most. The complications of the hypertension and coronary heart disease happened most. The support was 5.939% and 5.099% respectively. Fifty-five patients had the traditional Chinese medicine (TCM) syndrome of Qi-Yin deficiency, about 14.78% of the whole. There were 8 491 patients treated with the single dose of 81 to 100 mL, about 48.70% of the whole. The main combination drugs were dexamethasone, tropisetron and maxolon. The confidence was 44.63%, 31.22% and 20.53% respectively. The information from HIS showed that tumor patients used Shenmai injection were most quinquagenarian with smooth condition. The dose of the Shenmai injection sometimes was higher than that of the drug use instructions in clinical. Shenmai injection was most often combined with glucocorticoid, antemetic and nutritional support medicine when treating tumor in clinical.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25532386

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Effect of compound Zhuye Shigao Granule ( ) on acute radiation-induced esophagitis in cancer patients: A randomized controlled trial.

Authors:  Li-Juan Wang; Jun-Zhang Lu; Bo-Ning Cai; Ming-Wei Li; Bao-Lin Qu
Journal:  Chin J Integr Med       Date:  2016-12-29       Impact factor: 1.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.